Daan Gene: Guangzhou Pharmaceutical Group intends to acquire 233 million shares of the company.

Da An Gene announced on November 15, 2025 that Guangzhou Jinkong Group, Guangzhou Health Industry Investment, and Guangzhou Pharmaceutical Group signed the "Framework Agreement on the Acquisition of Controlling Rights of Guangzhou Da An Gene Co., Ltd." Guangzhou Pharmaceutical Group intends to acquire 100% equity of Guangyong Technology held by Guangzhou Jinkong Group, thereby indirectly controlling 2.33 billion shares of Da An Gene held by Guangyong Technology, as well as separately acquiring 70.1723 million shares of Da An Gene held by Guangzhou Jinkong Group and Guangzhou Health Industry Investment through agreement transfer. If the transaction is completed, Guangzhou Pharmaceutical Group will collectively control 374 million shares of the company, accounting for 26.63% of the total share capital, becoming the company's indirect controlling shareholder.